Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced two key corporate actions: First, the company has granted 4.5 million stock options to directors, officers, and consultants at $0.05 per share, with a five-year expiration and quarterly vesting schedule over one year. Second, the board has approved a shares-for-debt settlement of $67,800 through the issuance of 1,356,000 common shares at $0.05 per share to an arm’s length creditor.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) ha annunciato due importanti azioni aziendali: In primo luogo, la società ha concesso 4,5 milioni di opzioni su azioni a direttori, funzionari e consulenti a $0,05 per azione, con una scadenza di cinque anni e un programma di maturazione trimestrale nell’arco di un anno. In secondo luogo, il consiglio ha approvato un accordo di estinzione del debito tramite emissione di $67.800, attraverso l’emissione di 1.356.000 azioni ordinarie a $0,05 per azione a un creditore non correlato.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) ha anunciado dos acciones corporativas clave: Primero, la compañía ha otorgado 4.5 millones de opciones sobre acciones a directores, funcionarios y consultores a $0.05 por acción, con una expiración de cinco años y un calendario de adquisición trimestral durante un año. En segundo lugar, la junta ha aprobado un acuerdo de conversión de acciones por deuda de $67,800 mediante la emisión de 1,356,000 acciones ordinarias a $0.05 por acción a un acreedor independiente.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF)는 두 가지 주요 기업 조치를 발표했습니다: 첫째, 이 회사는 이사, 임원 및 컨설턴트에게 주당 $0.05로 450만 주식 옵션을 부여했으며, 만료일은 5년이며 1년 동안 분기마다 정기적으로 귀속됩니다. 둘째, 이사회는 팔을 뻗은 채 채무 상환을 위해 $67,800의 주식 발행을 승인했습니다. 주당 $0.05로 1,356,000주를 발행하여 독립된 채권자에게 지급합니다.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) a annoncé deux actions corporatives clés : Premièrement, la société a accordé 4,5 millions d’options d’achat d’actions à des directeurs, des dirigeants et des consultants à 0,05 $ par action, avec une date d’expiration de cinq ans et un calendrier d’acquisition trimestriel sur un an. Deuxièmement, le conseil d’administration a approuvé un règlement de dette par actions d’une valeur de 67 800 $ par l’émission de 1 356 000 actions ordinaires à 0,05 $ par action à un créancier indépendant.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) hat zwei wichtige Unternehmensmaßnahmen angekündigt: Erstens hat das Unternehmen 4,5 Millionen Aktienoptionen an Direktoren, Führungskräfte und Berater zu einem Preis von $0,05 pro Aktie gewährt, mit einer Laufzeit von fünf Jahren und einem vierteljährlichen Vesting-Plan über ein Jahr. Zweitens hat der Vorstand eine Schuldenregelung durch Aktienangebot genehmigt, in Höhe von $67,800, durch die Ausgabe von 1.356.000 Stammaktien zu $0,05 pro Aktie an einen unabhängigen Gläubiger.
Negative
- The company is diluting shareholders through new stock option grants of 4.5M shares
- Additional dilution through shares-for-debt settlement of 1.36M shares
- The company has outstanding debt that needs to be settled through share issuance, indicating potential cash flow issues
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI diagnostics, announces that it has granted an aggregate of 4,500,000 stock options (“Options“) to its directors, officers and consultants at a price of $0.05 per common share, expiring five years from the date of grant and vest one-fourth increments with the first batch being released on the three-month anniversary and the remaining three quarters vesting equally on the six-month, nine-month, and twelve-month anniversary of the date of grant. Each Option is exercisable to purchase one Common Share.
The Company also announces that its board of directors has approved the settlement of an aggregate of $67,800 of amount owing to an arm’s length creditor through the issuance of 1,356,000 common shares in the capital of the Company at $0.05 price per share to be determined at time of settlement.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a life sciences company focused on molecular hydrogen and AI diagnostics for brain health. DiagnaMed is exploring the medical use of hydrogen for brain health conditions, such as neurological and mental health disorders. In addition, the Company is commercializing BRAIN AGE® Brain Health AI Platform, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and nine months ended June 30, 2024 (“MD&A”), dated August 22, 2024, which is available on the Company’s profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
FAQ
How many stock options did DiagnaMed (DGNMF) grant in November 2023?
DiagnaMed granted 4,500,000 stock options to its directors, officers and consultants at a price of $0.05 per common share.
What is the vesting schedule for DiagnaMed’s (DGNMF) November 2023 stock options?
The options vest in four equal increments: 25% after three months, and the remaining portions at six, nine, and twelve months from the grant date.
How much debt is DiagnaMed (DGNMF) settling through share issuance?
DiagnaMed is settling $67,800 of debt through the issuance of 1,356,000 common shares at $0.05 per share.
